GLP-1 drugs like Wegovy are all the rage—but people are quitting them too fast to achieve meaningful weight loss, finds 170,000-patient study

A study of 170,000 patients reveals that users are discontinuing GLP-1 drugs, such as Wegovy, too quickly to reach significant weight loss goals. Despite this, antiobesity drug sales reached $1.1 billion during the second quarter of 2023. Simultaneously, the rise of these medications is influencing the food industry. Major restaurant chains, including McDonald's, Chipotle, and Shake Shack, are currently revamping their menus to adapt to the changing eating habits of consumers using weight-loss drugs.